Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one days post-infection. Forty-four S2P-specific monoclonal antibodies were generated, three of which bound to the receptor binding domain (RBD). The antibodies were minimally mutated from germline and were derived from different B cell lineages. Only two antibodies displayed neutralizing activity against SARS-CoV-2 pseudo-virus. The most potent antibody bound the RBD in a manner that prevented binding to the ACE2 receptor, while the other bound outside the RBD. Our study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 spike-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive/therapeutic potential and can serve as templates for vaccine-design. IN BRIEF: SARS-CoV-2 infection leads to expansion of diverse B cells clones against the viral spike glycoprotein (S). The antibodies bind S with high affinity despite being minimally mutated. Thus, the development of neutralizing antibody responses by vaccination will require the activation of certain naïve B cells without requiring extensive somatic mutation. Highlights: Analysis of early B cell response to SARS-CoV-2 spike protein Most antibodies target non-neutralizing epitopes Potent neutralizing mAb blocks the interaction of the S protein with ACE2 Neutralizing antibodies are minimally mutated
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 3×
“Indeed, the S proteins of the two viruses share a high degree of amino acid sequence homology; 76% overall and 74% in RBD (Wan et al., 2020).”
BackgroundSelf-citationLetko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · cited 2×
“High resolution structures of the SARS-CoV-2 prefusion-stabilized spike (S) ectodomain revealed that it adopts multiple conformations with either one receptor binding domain (RBD) in the “up” or “open” conformation or all RBDs in the “down” or “closed” conformation, similar to previous reports on both SARS-CoV S and M…”
ResultUnexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582
Commonality despite exceptional diversity in the baseline human antibody repertoire
Briney, B., Inderbitzin, A., Joyce, C., & Burton, D. R. (2019) · Nature · doi:10.1038/s41586-019-0879-y · Cited by 544
Tang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232 · cited 3×
“The RBD of MERS-CoV is also a target of potent neutralizing antibodies (Jiang et al., 2014; Niu et al., 2018; Tang et al., 2014; Ying et al., 2014), highlighting the importance of receptor blocking antibodies for coronavirus vaccine development.”
BackgroundRockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., & Baric, R. (2008) · Journal of Virology · doi:10.1128/jvi.02377-07 · Cited by 134 · cited 2×
“Moreover, the neutralizing potency correlated with the degree of S-ACE2 inhibition (Rockx et al., 2008).”
Background
Research works printed but not linked: 32
- 10.1093/nar/gkn316 · DOI · Paper page
- 2010, Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients, Virology journal, 7, 299, 10.1186/1743-422X-7-299 · DOI · Paper page
- Charif D, a.L.J. (2007). SeqinR 1.0–2: a contributed package to the R Project for statistical computing devoted to biological sequences retrieval and analysis (New York: Springer Verlag). · DOI · Paper page
- 10.1126/science.1205669 · DOI · Paper page
- Crawford, K.H.D. , Eguia, R. , Dingens, A.S. , Loes, A.N. , Malone, K.D. , Wolf, C.R. , Chu, H.Y. , Tortorici, M.A. , Veesler, D. , Murphy, M. , et al. (2020). Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. bioRxiv, 2020.2004.2020.051219. · DOI
- 10.1073/pnas.1525510113 · DOI · Paper page
- 2020, An interactive web-based dashboard to track COVID-19 in real time, The Lancet infectious diseases, 20, 533, 10.1016/S1473-3099(20)30120-1 · DOI · Paper page
- 10.1038/cr.2016.152 · DOI · Paper page
- 10.1016/j.cell.2020.02.052 · DOI · Paper page
- 10.1074/jbc.M603275200 · DOI · Paper page
- 2014, Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein, Science translational medicine, 6, 234
- 2018, Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Scientific reports, 8, 15701, 10.1038/s41598-018-34171-7 · DOI · Paper page
- 10.1038/nature02145 · DOI · Paper page
- 10.1038/nature09385 · DOI · Paper page
- 10.1093/infdis/jiy311 · DOI · Paper page
- Okba, N.M.A. , Muller, M.A. , Li, W. , Wang, C. , GeurtsvanKessel, C.H. , Corman, V.M. , Lamers, M.M. , Sikkema, R.S. , de Bruin, E. , Chandler, F.D. , et al. (2020). Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerging infectious diseases 26. · DOI · Paper page
- 2020, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nature communications, 11, 1620, 10.1038/s41467-020-15562-9 · DOI · Paper page
- 10.1074/jbc.M600697200 · DOI · Paper page
- 10.1016/j.immuni.2018.03.026 · DOI · Paper page
- 10.1371/journal.ppat.1007236 · DOI · Paper page
- 10.1038/s41586-019-0934-8 · DOI · Paper page
- 10.1073/pnas.0307140101 · DOI · Paper page
- 10.1016/j.jim.2007.09.017 · DOI · Paper page
- 10.1038/nm1080 · DOI · Paper page
- 2019, High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis, Frontiers in immunology, 10, 660, 10.3389/fimmu.2019.00660 · DOI · Paper page
- 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nature communications, 11, 2251, 10.1038/s41467-020-16256-y · DOI · Paper page
- 10.1126/science.abb2507 · DOI · Paper page
- 10.1128/JVI.00912-14 · DOI · Paper page
- 2015, Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody, Nature communications, 6, 8223, 10.1038/ncomms9223 · DOI · Paper page
- Yuan, M. , Wu, N.C. , Zhu, X. , Lee, C.D. , So, R.T.Y. , Lv, H. , Mok, C.K.P. , and Wilson, I.A. (2020). A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. · DOI
- 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nature communications, 8, 15092, 10.1038/ncomms15092 · DOI · Paper page
Cited by
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
“Recent studies have shown that related, potently neutralizing monoclonal antibodies that recognize the SARS-CoV-2 receptor binding domain (RBD) are often elicited in SARS-CoV-2 infection (3-17).”
BackgroundA human monoclonal antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B.-J. (2020) · Nature Communications · doi:10.1038/s41467-020-16256-y · Cited by 1,132
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
Metadata
- Authors
- Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Nelson, R. E., Singh, S., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2020-05-12
- OpenAlex
- W3025262235
- Cited by
- 64
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. https://app.cochat.ai/papers/10.1101/2020.05.12.091298
- The paper
- Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Nelson, R. E., Singh, S., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L. (2020). Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.05.12.091298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.